Harald Hoffmann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Harald Hoffmann has a total of 152 co-authors. Here are the top co-authors by number of shared publications:
Sabine Hofmann-Thiel
Department IML red GmbH, WHO - Supranational Tuberculosis Reference Laboratory, Institute of Microbiology and Laboratory Medicine
4 shared publicationsMarion Heiß-Neumann
Kuratorium Tuberkulose in der Welt e.V.
3 shared publications- Stefan Niemann
Research Centre Borstel Leibniz Lung Center, Molecular and Experimental Mycobacteriology, Borstel, Germany.
3 shared publications Uladzimir Antonenka
Department IML red GmbH, WHO - Supranational Tuberculosis Reference Laboratory, Institute of Microbiology and Laboratory Medicine
3 shared publicationsCaroline Corbett
Institute of Microbiology and Laboratory Medicine
2 shared publicationsChristian Utpatel
Molecular and Experimental Mycobacteriology, Research Center Borstel, Borstel, Germany
2 shared publications
Latest Publications
- Open Access
- 11 February 2026
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 64 (2) , e0138825
Tuberculosis diagnosis and the complete drug resistance pattern from a single sample within a single day by use of a composite platform of MAX MDR-TB and AmPORE-TB
Rapid TB diagnostics are essential for effective TB control. Combining WHO-recommended rapid molecular tests with downstream targeted next-generation sequencing (tNGS) enables faster drug resistance profiling. The objective of this study was to establish a one-day diagnostic platform (ODDP) integrating BD MAX MDR-TB and AmPORE-TB tNGS from a single sample. Pooled sputum samples spiked with 52 pre-characterized Mycobacterium tuberculosis (MTB) strains and 74 MTB-positive clinical samples were tested using BD MAX MDR-TB for TB, isoniazid, and rifampicin resistance. tNGS was performed from 5 µL of purified DNA leftover for each TB-positive sample in the BD MAX strips. IS6110/IS1081 Ct-values served as surrogate markers for TB DNA concentration. A total of 104 spiked and 60 clinical samples tested positive by BD MAX. The average time to the final ODDP result was 8.5 h. For samples with Ct ≤28, tNGS generated antibiotic resistance profiles for ≥12 antibiotics with 85.1% sensitivity in spiked and 73% in clinical samples. Failure rates were 10% and 8.3%, respectively. Resistance profiling most frequently (up to 11.3%) failed for clofazimine, pretomanid, and delamanid. The ODDP enables comprehensive TB diagnosis and resistance profiling from a single sample in 1 day. This platform can significantly accelerate the time to informed drug-resistant (DR)-TB treatment decisions. IMPORTANCE: Reducing the time to treatment initiation decreases patient drop-out rates, morbidity, the emergence of new drug resistances, and onward transmission of infection. Obtaining the complete resistome from the start is crucial for choosing a fully effective treatment regimen. Until now, diagnosis with full resistance profiling has required at least two sputum samples and 3 to 7 days for the complete workflow, obliging patients to return two to three times, which dramatically increased the risk of loss to follow-up. Our one-day diagnostic platform enables both diagnosis and comprehensive resistance testing from a single sample within 1 day. Patients can remain in a day clinic during testing and receive a fully effective, individualized treatment regimen the same day. This approach is expected to markedly reduce morbidity, drop-out rates, and transmission. The necessary instruments and technologies are already available in many high-prevalence countries and are currently being rapidly scaled up worldwide.
- 11 February 2026
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 64 (2) , e0138825
Open AccessTuberculosis diagnosis and the complete drug resistance pattern from a single sample within a single day by use of a composite platform of MAX MDR-TB and AmPORE-TB
Rapid TB diagnostics are essential for effective TB control. Combining WHO-recommended rapid molecular tests with downstream targeted next-generation sequencing (tNGS) enables faster drug resistance profiling. The objective of this study was to establish a one-day diagnostic platform (ODDP) integrating BD MAX MDR-TB and AmPORE-TB tNGS from a single sample. Pooled sputum samples spiked with 52 pre-characterized Mycobacterium tuberculosis (MTB) strains and 74 MTB-positive clinical samples were tested using BD MAX MDR-TB for TB, isoniazid, and rifampicin resistance. tNGS was performed from 5 µL of purified DNA leftover for each TB-positive sample in the BD MAX strips. IS6110/IS1081 Ct-values served as surrogate markers for TB DNA concentration. A total of 104 spiked and 60 clinical samples tested positive by BD MAX. The average time to the final ODDP result was 8.5 h. For samples with Ct ≤28, tNGS generated antibiotic resistance profiles for ≥12 antibiotics with 85.1% sensitivity in spiked and 73% in clinical samples. Failure rates were 10% and 8.3%, respectively. Resistance profiling most frequently (up to 11.3%) failed for clofazimine, pretomanid, and delamanid. The ODDP enables comprehensive TB diagnosis and resistance profiling from a single sample in 1 day. This platform can significantly accelerate the time to informed drug-resistant (DR)-TB treatment decisions. IMPORTANCE: Reducing the time to treatment initiation decreases patient drop-out rates, morbidity, the emergence of new drug resistances, and onward transmission of infection. Obtaining the complete resistome from the start is crucial for choosing a fully effective treatment regimen. Until now, diagnosis with full resistance profiling has required at least two sputum samples and 3 to 7 days for the complete workflow, obliging patients to return two to three times, which dramatically increased the risk of loss to follow-up. Our one-day diagnostic platform enables both diagnosis and comprehensive resistance testing from a single sample within 1 day. Patients can remain in a day clinic during testing and receive a fully effective, individualized treatment regimen the same day. This approach is expected to markedly reduce morbidity, drop-out rates, and transmission. The necessary instruments and technologies are already available in many high-prevalence countries and are currently being rapidly scaled up worldwide.
- Open Access
- 11 July 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (1) , 2400391
A composite reference standard is needed for bedaquiline antimicrobial susceptibility testing forMycobacterium tuberculosiscomplex
Shareable abstract A composite reference standard minimises false-susceptible AST results for bedaquilinehttps://bit.ly/3wAVvFm
- 11 July 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (1) , 2400391
Open AccessA composite reference standard is needed for bedaquiline antimicrobial susceptibility testing forMycobacterium tuberculosiscomplex
Shareable abstract A composite reference standard minimises false-susceptible AST results for bedaquilinehttps://bit.ly/3wAVvFm
- Open Access
- 26 April 2024
- Published by MDPI AG in Proceedings
- Vol. 97 (1) , 208
Sample Preparation and qPCR Detection of Tuberculosis on a Centrifugal Microfluidic Cartridge Enabling Molecular Downstream Resistance Profiling
Tuberculosis (TB) is still one of the world’s deadliest infections. Fast detection of the pathogen M. tuberculosis (MTB) and its genetic resistance markers substantially improves treatment success and outcome. A key element for rapid genetic diagnostics is the efficient extraction of DNA from sputum for qPCR detection at the point of care. We present the fully automated sample preparation of MTB DNA from 3 mL of liquefied sputum and qPCR detection of MTB on a centrifugal microfluidic cartridge. Our method achieves a limit of detection (LoD) between 17 and 57 CFU/mL and provides a purified DNA solution for molecular downstream testing, such as targeted NGS.
- 26 April 2024
- Published by MDPI AG in Proceedings
- Vol. 97 (1) , 208
Open AccessSample Preparation and qPCR Detection of Tuberculosis on a Centrifugal Microfluidic Cartridge Enabling Molecular Downstream Resistance Profiling
Tuberculosis (TB) is still one of the world’s deadliest infections. Fast detection of the pathogen M. tuberculosis (MTB) and its genetic resistance markers substantially improves treatment success and outcome. A key element for rapid genetic diagnostics is the efficient extraction of DNA from sputum for qPCR detection at the point of care. We present the fully automated sample preparation of MTB DNA from 3 mL of liquefied sputum and qPCR detection of MTB on a centrifugal microfluidic cartridge. Our method achieves a limit of detection (LoD) between 17 and 57 CFU/mL and provides a purified DNA solution for molecular downstream testing, such as targeted NGS.
- Open Access
- 6 December 2023
- Published by Taylor & Francis in Emerging Microbes & Infections
- Vol. 12 (2) , 2276342
Development of prevalence and incidence of non-tuberculous mycobacteria in German laboratories from 2016 to 2020
Numbers of non-tuberculous mycobacteria (NTM) pulmonary diseases (PD) have been repeatedly reported as increasing over the last decades, particularly in Europe. Sound epidemiological data are however missing for most European regions. This study calculated prevalence and incidence of NTM recovered from patients' lungs in Germany, the largest Central European country, over a five-year period. It furthermore determined regional particularities of NTM species and results from susceptibility testing. 22 German NTM laboratories provided their mycobacteriological diagnostic data of 11,430 NTM isolates recovered from 5998 pulmonary patients representing 30% of all notified NTM-PD cases of Germany from 2016 to 2020. NTM incidence and prevalence were calculated for every study year. The presented epidemiological indicators are particularly reliant as TB surveillance data were used as a reference and TB notification reaches almost 100% in Germany. Laboratory incidence and prevalence of NTM recovered from respiratory samples ranged from 4.5-4.9 and from 5.3-5.8/100,000 for the population of Germany, respectively, and did not change over the five-year study period. Prevalence and incidence were stable also when stratifying for facultative pathogenic NTM, M. avium/intracellulare complex (MAIC), and M. abscessus/chelonae complex (MABSC). The proportion of NTM with drug susceptibility testing (DST) increased from 27.3% (2016) to 43.8% (2020). The unchanging laboratory NTM prevalence/incidence in Germany represents a "ceiling" of possible NTM-PD notification when diagnostic strategies do not change in the coming years. A notable increase in NTM-DST may indicate better notification of NTM-PD and/or awareness of new clinical guidelines but still remains below clinical needs.
- 6 December 2023
- Published by Taylor & Francis in Emerging Microbes & Infections
- Vol. 12 (2) , 2276342
Open AccessDevelopment of prevalence and incidence of non-tuberculous mycobacteria in German laboratories from 2016 to 2020
Numbers of non-tuberculous mycobacteria (NTM) pulmonary diseases (PD) have been repeatedly reported as increasing over the last decades, particularly in Europe. Sound epidemiological data are however missing for most European regions. This study calculated prevalence and incidence of NTM recovered from patients' lungs in Germany, the largest Central European country, over a five-year period. It furthermore determined regional particularities of NTM species and results from susceptibility testing. 22 German NTM laboratories provided their mycobacteriological diagnostic data of 11,430 NTM isolates recovered from 5998 pulmonary patients representing 30% of all notified NTM-PD cases of Germany from 2016 to 2020. NTM incidence and prevalence were calculated for every study year. The presented epidemiological indicators are particularly reliant as TB surveillance data were used as a reference and TB notification reaches almost 100% in Germany. Laboratory incidence and prevalence of NTM recovered from respiratory samples ranged from 4.5-4.9 and from 5.3-5.8/100,000 for the population of Germany, respectively, and did not change over the five-year study period. Prevalence and incidence were stable also when stratifying for facultative pathogenic NTM, M. avium/intracellulare complex (MAIC), and M. abscessus/chelonae complex (MABSC). The proportion of NTM with drug susceptibility testing (DST) increased from 27.3% (2016) to 43.8% (2020). The unchanging laboratory NTM prevalence/incidence in Germany represents a "ceiling" of possible NTM-PD notification when diagnostic strategies do not change in the coming years. A notable increase in NTM-DST may indicate better notification of NTM-PD and/or awareness of new clinical guidelines but still remains below clinical needs.
- Open Access
- 27 October 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (11) , 2543
A Single-Run HPLC–MS Multiplex Assay for Therapeutic Drug Monitoring of Relevant First- and Second-Line Antibiotics in the Treatment of Drug-Resistant Tuberculosis
The treatment of drug-resistant Mycobacterium tuberculosis relies on complex antibiotic therapy. Inadequate antibiotic exposure can lead to treatment failure, acquired drug resistance, and an increased risk of adverse events. Therapeutic drug monitoring (TDM) can be used to optimize the antibiotic exposure. Therefore, we aimed to develop a single-run multiplex assay using high-performance liquid chromatography–mass spectrometry (HPLC–MS) for TDM of patients with multidrug-resistant, pre-extensively drug-resistant and extensively drug-resistant tuberculosis. A target profile for sufficient performance, based on the intended clinical application, was established and the assay was developed accordingly. Antibiotics were analyzed on a zwitterionic hydrophilic interaction liquid chromatography column and a triple quadrupole mass spectrometer using stable isotope-labeled internal standards. The assay was sufficiently sensitive to monitor drug concentrations over five half-lives for rifampicin, rifabutin, levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, terizidone/cycloserine, ethambutol, delamanid, pyrazinamide, meropenem, prothionamide, and para-amino salicylic acid (PAS). Accuracy and precision were sufficient to support clinical decision making (≤±15% in clinical samples and ±20–25% in spiked samples, with 80% of future measured concentrations predicted to fall within ±40% of nominal concentrations). The method was applied in the TDM of two patients with complex drug-resistant tuberculosis. All relevant antibiotics from their regimens could be quantified and high-dose therapy was initiated, followed by microbiological conversion. In conclusion, we developed a multiplex assay that enables TDM of the relevant first- and second-line anti-tuberculosis medicines in a single run and was able to show its applicability in TDM of two drug-resistant tuberculosis patients.
- 27 October 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (11) , 2543
Open AccessA Single-Run HPLC–MS Multiplex Assay for Therapeutic Drug Monitoring of Relevant First- and Second-Line Antibiotics in the Treatment of Drug-Resistant Tuberculosis
The treatment of drug-resistant Mycobacterium tuberculosis relies on complex antibiotic therapy. Inadequate antibiotic exposure can lead to treatment failure, acquired drug resistance, and an increased risk of adverse events. Therapeutic drug monitoring (TDM) can be used to optimize the antibiotic exposure. Therefore, we aimed to develop a single-run multiplex assay using high-performance liquid chromatography–mass spectrometry (HPLC–MS) for TDM of patients with multidrug-resistant, pre-extensively drug-resistant and extensively drug-resistant tuberculosis. A target profile for sufficient performance, based on the intended clinical application, was established and the assay was developed accordingly. Antibiotics were analyzed on a zwitterionic hydrophilic interaction liquid chromatography column and a triple quadrupole mass spectrometer using stable isotope-labeled internal standards. The assay was sufficiently sensitive to monitor drug concentrations over five half-lives for rifampicin, rifabutin, levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, terizidone/cycloserine, ethambutol, delamanid, pyrazinamide, meropenem, prothionamide, and para-amino salicylic acid (PAS). Accuracy and precision were sufficient to support clinical decision making (≤±15% in clinical samples and ±20–25% in spiked samples, with 80% of future measured concentrations predicted to fall within ±40% of nominal concentrations). The method was applied in the TDM of two patients with complex drug-resistant tuberculosis. All relevant antibiotics from their regimens could be quantified and high-dose therapy was initiated, followed by microbiological conversion. In conclusion, we developed a multiplex assay that enables TDM of the relevant first- and second-line anti-tuberculosis medicines in a single run and was able to show its applicability in TDM of two drug-resistant tuberculosis patients.
- Open Access
Origin and Global Expansion of Mycobacterium tuberculosis Complex Lineage 3
Mycobacterium tuberculosis complex (MTBC) Lineage 3 (L3) strains are abundant in world regions with the highest tuberculosis burden. To investigate the population structure and the global diversity of this major lineage, we analyzed a dataset comprising 2682 L3 strains from 38 countries over 5 continents, by employing 24-loci mycobacterial interspersed repetitive unit-variable number of tandem repeats genotyping (MIRU-VNTR) and drug susceptibility testing. We further combined whole-genome sequencing (WGS) and phylogeographic analysis for 373 strains representing the global L3 genetic diversity. Ancestral state reconstruction confirmed that the origin of L3 strains is located in Southern Asia and further revealed multiple independent introduction events into North-East and East Africa. This study provides a systematic understanding of the global diversity of L3 strains and reports phylogenetic variations that could inform clinical trials which evaluate the effectivity of new drugs/regimens or vaccine candidates.
Open AccessOrigin and Global Expansion of Mycobacterium tuberculosis Complex Lineage 3
Mycobacterium tuberculosis complex (MTBC) Lineage 3 (L3) strains are abundant in world regions with the highest tuberculosis burden. To investigate the population structure and the global diversity of this major lineage, we analyzed a dataset comprising 2682 L3 strains from 38 countries over 5 continents, by employing 24-loci mycobacterial interspersed repetitive unit-variable number of tandem repeats genotyping (MIRU-VNTR) and drug susceptibility testing. We further combined whole-genome sequencing (WGS) and phylogeographic analysis for 373 strains representing the global L3 genetic diversity. Ancestral state reconstruction confirmed that the origin of L3 strains is located in Southern Asia and further revealed multiple independent introduction events into North-East and East Africa. This study provides a systematic understanding of the global diversity of L3 strains and reports phylogenetic variations that could inform clinical trials which evaluate the effectivity of new drugs/regimens or vaccine candidates.
- Open Access
- 28 July 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-9
Implementation of whole genome sequencing for tuberculosis diagnostics in a low-middle income, high MDR-TB burden country
Whole genome sequencing (WGS) is revolutionary for diagnostics of TB and its mutations associated with drug-resistances, but its uptake in low- and middle-income countries is hindered by concerns of implementation feasibility. Here, we provide a proof of concept for its successful implementation in such a setting. WGS was implemented in the Kyrgyz Republic. We estimated needs of up to 55 TB-WGS per week and chose the MiSeq platform (Illumina, USA) because of its capacity of up to 60 TB-WGS per week. The project’s timeline was completed in 93-weeks. Costs of large equipment and accompanying costs were 222,065 USD and 8462 USD, respectively. The first 174 WGS costed 277 USD per sequence, but this was skewed by training inefficiencies. Based on real prices and presuming optimal utilization of WGS capacities, WGS costs could drop to 167 and 141 USD per WGS using MiSeq Reagent Kits v2 (500-cycles) and v3 (600-cycles), respectively. Five trainings were required to prepare the staff for autonomous WGS which cost 48,250 USD. External assessment confirmed excellent performance of WGS by the Kyrgyz laboratory in an interlaboratory comparison of 30 M. tuberculosis genomes showing complete agreeance of results.
- 28 July 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-9
Open AccessImplementation of whole genome sequencing for tuberculosis diagnostics in a low-middle income, high MDR-TB burden country
Whole genome sequencing (WGS) is revolutionary for diagnostics of TB and its mutations associated with drug-resistances, but its uptake in low- and middle-income countries is hindered by concerns of implementation feasibility. Here, we provide a proof of concept for its successful implementation in such a setting. WGS was implemented in the Kyrgyz Republic. We estimated needs of up to 55 TB-WGS per week and chose the MiSeq platform (Illumina, USA) because of its capacity of up to 60 TB-WGS per week. The project’s timeline was completed in 93-weeks. Costs of large equipment and accompanying costs were 222,065 USD and 8462 USD, respectively. The first 174 WGS costed 277 USD per sequence, but this was skewed by training inefficiencies. Based on real prices and presuming optimal utilization of WGS capacities, WGS costs could drop to 167 and 141 USD per WGS using MiSeq Reagent Kits v2 (500-cycles) and v3 (600-cycles), respectively. Five trainings were required to prepare the staff for autonomous WGS which cost 48,250 USD. External assessment confirmed excellent performance of WGS by the Kyrgyz laboratory in an interlaboratory comparison of 30 M. tuberculosis genomes showing complete agreeance of results.
- 1 October 2020
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 22 (10) , 1280-1286
Clinical Evaluation of BD MAX MDR-TB Assay for Direct Detection of Mycobacterium tuberculosis Complex and Resistance Markers
- 1 October 2020
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 22 (10) , 1280-1286
Clinical Evaluation of BD MAX MDR-TB Assay for Direct Detection of Mycobacterium tuberculosis Complex and Resistance Markers
- 28 February 2020
- Published by Georg Thieme Verlag KG in Pneumologie
- Vol. 74 (S 01) , P432-S110
Therapeutic drug monitoring in the treatment of M/XDR RB
Introduction: With more than 1.6 million deaths in 2017, tuberculosis (TB) is currently the leading cause of death by a single pathogen. The WHOʼs plans to drastically reduce TB incidence and mortality by 2035 is hampered by emerging drug resistance: The management of patients with multidrug-resistant TB (MDR-TB) and especially extensively drug-resistant TB (XDR-TB) it is costly and the drug regimens often lead to adverse drug events. Acquired drug resistance (ADR) on inadequate treatment regimens is regularly observed. Therapeutic drug monitoring (TDM) can individually optimise the dosages of drugs thus reducing the risk for ADR and adverse events. We present the effect of individualised drug dosages based on TDM for a patient with advanced XDR-TB. Methods: In a 34 y/o male patient from Ukraine with phenotypic resistance against all 2nd-line anti-TB drugs (SLDs) except for delamanid, we evaluated minimal inhibitory concentrations (MIC) of the causative M. tuberculosis strain against all SLDs by TREK plate analysis and SLD-plasma-blood-levels by HPLC-MS². Drug levels were adjusted according to the results of the analysis. Results: We identified intermediate level resistance against bedaquiline, moxifloxacin and cycloserine based on the MIC determination. Following the analysis of plasma concentrations of 2nd-line anti-TB agents by HPLC-MS², drug dosages were adjusted to bedaquiline 300 mg once daily 3 ×/week, moxifloxacin 1.6 g once daily, meropenem/amoxicillin/clavulanate 2 g/875 mg/125 mg trice daily, PAS13 g once daily, delamanid 100 mg twice daily, ethambutol 2.5 g once daily and terizidone 1 g once daily under careful clinical monitoring for adverse drug events. Time to culture positivity increased from 25 days to > 40 days on modified anti-TB treatment within 24 weeks. Conclusion: Therapeutic drug monitoring could become a useful clinical tool to individualise treatment regimens for patients with M/XDR-TB where therapeutic options are limited.
- 28 February 2020
- Published by Georg Thieme Verlag KG in Pneumologie
- Vol. 74 (S 01) , P432-S110
Therapeutic drug monitoring in the treatment of M/XDR RB
Introduction: With more than 1.6 million deaths in 2017, tuberculosis (TB) is currently the leading cause of death by a single pathogen. The WHOʼs plans to drastically reduce TB incidence and mortality by 2035 is hampered by emerging drug resistance: The management of patients with multidrug-resistant TB (MDR-TB) and especially extensively drug-resistant TB (XDR-TB) it is costly and the drug regimens often lead to adverse drug events. Acquired drug resistance (ADR) on inadequate treatment regimens is regularly observed. Therapeutic drug monitoring (TDM) can individually optimise the dosages of drugs thus reducing the risk for ADR and adverse events. We present the effect of individualised drug dosages based on TDM for a patient with advanced XDR-TB. Methods: In a 34 y/o male patient from Ukraine with phenotypic resistance against all 2nd-line anti-TB drugs (SLDs) except for delamanid, we evaluated minimal inhibitory concentrations (MIC) of the causative M. tuberculosis strain against all SLDs by TREK plate analysis and SLD-plasma-blood-levels by HPLC-MS². Drug levels were adjusted according to the results of the analysis. Results: We identified intermediate level resistance against bedaquiline, moxifloxacin and cycloserine based on the MIC determination. Following the analysis of plasma concentrations of 2nd-line anti-TB agents by HPLC-MS², drug dosages were adjusted to bedaquiline 300 mg once daily 3 ×/week, moxifloxacin 1.6 g once daily, meropenem/amoxicillin/clavulanate 2 g/875 mg/125 mg trice daily, PAS13 g once daily, delamanid 100 mg twice daily, ethambutol 2.5 g once daily and terizidone 1 g once daily under careful clinical monitoring for adverse drug events. Time to culture positivity increased from 25 days to > 40 days on modified anti-TB treatment within 24 weeks. Conclusion: Therapeutic drug monitoring could become a useful clinical tool to individualise treatment regimens for patients with M/XDR-TB where therapeutic options are limited.
- 1 November 2016
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 194 (9) , 1171-1172
Reply: Call for Regular Susceptibility Testing of Bedaquiline and Delamanid
- 1 November 2016
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 194 (9) , 1171-1172
Reply: Call for Regular Susceptibility Testing of Bedaquiline and Delamanid